Figure 2From: Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugsDistribution of signature scores across 15 cancer types. A: Distribution of NtAI scores. B: Distribution of LST scores. C: Distribution of HRD-LOH scores. Horizontal black lines indicate 25th, 50th and 75th percentiles.Back to article page